This specific human monoclonal antibody h128-3 blocks the inhibitory signaling that would normally occur upon LILRB4 binding to APOE by binding to LILRB4, resulting in effective treatment of AML by reversing the multiple effects of T-cell suppression, inhibiting tissue infiltration of AML cells by monocytes and attenuating antibody-dependent cytotoxicity and antibody-dependent cellular phagocytosis. This evidence concerns the gene APOE and acute myeloid leukemia.